Cellular therapy of systemic sclerosis

Current Rheumatology Reports

Volumn 10, Issue 3, 2008, Pages 189-194

  van Laar, Jacob M ^b   Tyndall, Alan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MESENCHYMAL STEM CELL; NONHUMAN; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANIMAL; DISEASE MODEL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 51449098855     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0032-7     Document Type: Review

References (62)

1. Thomas ED: The Nobel Lectures in Immunology. The Nobel Prize for Physiology or Medicine, 1990. Bone marrow transplantation - past, present and future. Scand J Immunol 1994, 39:339-345.
2. Marmont AM: Stem cell transplantation for autoimmune disorders. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol 2004, 17:223-232.
3. Muraro PA, Douek DC, Packer A, et al.: Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005, 201:805-816.
4. Farge D, Henegar C, Carmagnat M, et al.: Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 2005, 52:1555-1563.
5. Le Blanc K, Rasmusson I, Sundberg B, et al.: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
6. Taupin P: OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Curr Opin Investig Drugs 2006, 7:473-481.
7. van Laar JM, Tyndall A: Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006, 45:1187-1193.
8. Gratwohl A, Passweg J, Bocelli-Tyndall C, et al.: Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005, 35:869-879.
9. Binks M, Passweg JR, Furst D, et al.: Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001, 60:577-584.
10. Farge D, Passweg J, van Laar JM, et al.: Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004, 63:974-981.
11. Nash RA, McSweeney PA, Crofford LJ, et al.: High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007, 110:1388-1396.
12. Vonk MC, Marjanovic Z, van den Hoogen FH, et al.: Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008, 67:98-104.
13. Fleming JN, Nash RA, McLeod DO, et al.: Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 2008, 3:e1452.
14. Aschwanden M, Daikeler T, Jaeger K, et al.: Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue damage. Ann Rheum Dis 2008 (in press).
15. van Laar JM, Farge D, Tyndall A: Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005, 64:1515.
16. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP: Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968, 6:230-247.
17. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI: Characterization of cells with osteogenic potential from human marrow. Bone 1992, 13:81-88.
18. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
19. Pittenger MF, Mackay AM, Beck SC, et al.: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
20. Friedenstein AJ, Deriglasova UF, Kulagina NN, et al.: Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974, 2:83-92.
21. Nakahara H, Dennis JE, Bruder SP, et al.: In vitro differentiation of bone and hypertrophic cartilage from periosteal-derived cells. Exp Cell Res 1991, 195:492-503.
22. Sampath TK, Nathanson MA, Reddi AH: In vitro transformation of mesenchymal cells derived from embryonic muscle into cartilage in response to extracellular matrix components of bone. Proc Natl Acad Sci U S A 1984, 81:3419-3423.
23. Jones EA, Kinsey SE, English A, et al.: Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 2002, 46:3349-3360.
24. Bieback K, Kluter H: Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther 2007, 2:310-323.
25. Soncini M, Vertua E, Gibelli L, et al.: Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med 2007, 1:296-305.
26. Horwitz E, Le Blanc K, Dominici M, et al.: Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005, 7:393-395.
27. Tyndall A, LeBlanc K: Stem cells and rheumatology: update on adult stem cell therapy in autoimmune diseases. Arthritis Rheum 2006, 55:521-525.
28. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al.: Donorderived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood 2006, 108:2114-2120.
29. Eliopoulos N, Stagg J, Lejeune L, et al.: Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005, 106:4057-4065.
30. Tse WT, Pendleton JD, Beyer WM, et al.: Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75:389-397.
31. Le Blanc K, Tammik L, Sundberg B, et al.: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
32. Di Nicola M, Carlo-Stella C, Magni M, et al.: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
33. Klyushnenkova E, Mosca JD, Zernetkina V, et al.: T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005, 12:47-57.
34. Krampera M, Glennie S, Dyson J, et al.: Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
35. Bartholomew A, Sturgeon C, Siatskas M, et al.: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
36. Corcione A, Benvenuto F, Ferretti E, et al.: Human mesenchymal stem cells modulate B cell functions. Blood 2006, 107:367-372.
37. Glennie S, Soeiro I, Dyson PJ, et al.: Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105:2821-2827.
38. Rasmusson I, Ringden O, Sundberg B, Le Blanc K: Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003, 76:1208-1213.
39. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
40. Meisel R, Zibert A, Laryea M, et al.: Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
41. Sato K, Ozaki K, Oh I, et al.: Nitric oxide plays a critical role in suppression of T cell proliferation by mesenchymal stem cells. Blood 2006, 109:228-234.
42. Nasef A, Mathieu N, Chapel A, et al.: Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007, 84:231-237.
43. Ortiz LA, Gambelli F, McBride C, et al.: Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003, 100:8407-8411.
44. Fang B, Shi M, Liao L, et al.: Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation 2004, 78:83-88.
45. Togel F, Hu Z, Weiss K, et al.: Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005, 289:F31-F42.
46. Togel F, Weiss K, Yang Y, et al.: Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007, 292:F1626-F1635.
47. Bocelli-Tyndall C, Bracci L, Spagnoli G, et al.: Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) 2007, 46:403-408.
48. Larghero J, Farge D, Braccini A, et al.: Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from systemic sclerosis patients. Ann Rheum Dis 2007 (Epub ahead of print).
49. Cipriani P, Guiducci S, Miniati I, et al.: Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007, 56:1994-2004.
50. Ball SG, Shuttleworth CA, Kielty CM: Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors. J Cell Mol Med 2007, 11:1012-1030.
51. Djouad F, Plence P, Bony C, et al.: Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
52. Zhang J, Li Y, Chen J, et al.: Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005, 195:16-26.
53. Zappia E, Casazza S, Pedemonte E, et al.: Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
54. Djouad F, Fritz V, Apparailly F, et al.: Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005, 52:1595-1603.
55. Augello A, Tasso R, Negrini SM, et al.: Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007, 56:1175-1186.
56. Lazarus HM, Haynesworth SE, Gerson SL, et al.: Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995, 16:557-564.
57. Lazarus HM, Koc ON, Devine SM, et al.: Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11:389-398.
58. Koc ON, Day J, Nieder M, et al.: Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002, 30:215-222.
59. Koc ON, Gerson SL, Cooper BW, et al.: Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000, 18:307-316.
60. Horwitz EM, Gordon PL, Koo WK, et al.: Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002, 99:8932-8937.
61. Fouillard L, Bensidhoum M, Bories D, et al.: Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia 2003, 17:474-476.
62. Le Blanc K, Fibbe W: A new cell therapy registry coordinated by the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2008, 41:319.